<DOC>
	<DOC>NCT02814500</DOC>
	<brief_summary>An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212</brief_summary>
	<brief_title>DP-R212 Pharmacokinetic Study Phase I</brief_title>
	<detailed_description>An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212, a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers</detailed_description>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>BMI 17.5~30.5 signed the informed consent form prior to the study participation Clinically significant disease Previously donate whole blood within 60 days or component blood within 30 days Clinically significant allergic disease Taken IP in other trial within 90 days An impossible one who participates in clinical trial by investigator's decision including laboratory test result</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>